Effects of Inflammatory Biomarkers (Fetuin-A and High Sensitivity C-reactive Protein) on Glycemic Control in Type 2 Diabetic Women
Article Sidebar
Main Article Content
Abstract
Objective Inflammation plays an essential role in the development of insulin resistance and type 2 diabetes. The objective of this study was to evaluate the effects of inflammatory markers (hs-CRP and fetuin-A) on glycemic control in Iraqi women patients with type 2 diabetes, and to examine the correlation of these markers with indices of glycemic control.
Methods This case-control study included 45 Iraqi type 2 diabetic female patients and 44 non-diabetic Iraqi female patients matched for age and sex as control subjects. For both patients and controls hs-CRP and fetuin-A were measured using ELISA, HbA1c by the turbidimetric immunoassay, FBG and lipid profile measures using the spectrophotometer method.
Results High levels of both fetuin-A and hs-CRP were observed in diabetic patients compared to the healthy controls. hs-CRP was significantly higher in the diabetic group 3.1 ± 0.59 mg/dL than the control 1.22 ± 0.66 mg/dL and was statistically significantly correlated with the marker of glycemic control (p < 0.001). The serum level of fetuin-A in the diabetic group (768.7 ± 173.03 µg/mL) was also significantly higher than that of control (311.95 ± 94.13 µg/mL) (p < 0.001). A strong positive correlation was observed between fetuin-A concentrations with serum hs-CRP concentrations in the diabetic individuals but not in the controls.
Conclusions Diabetic Iraqi women have higher inflammatory markers (fetuin-A and hs-CRP) than non-diabetic women. A strong association was observed for these inflammatory biomarkers and glycemic control in diabetic subjects.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine. 2019;47:22-7.
Cruz M, Valladares-Salgado A, Flores-Alfaro E, Romero JdJP. Genetic determinants of type 2 diabetes. the diabetes textbook. Cham, Switzerland: Springer; 2019. p. 117-25.
Fadaei R, Bagheri N, Heidarian E, Nouri A, Hesari Z, Moradi N, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF- and IL-6. Cytokine. 2020;125:154832. PubMed PMID: 31479874
Al-bayati AAH, AL-Khateeb SM, Ali EA. COVID-19 and preexisted diabetes, one insults the other narrative review”. J Saudi J Biomed Res. 2021;6:137-47.
Trepanowski J, Mey J, Varady K. Fetuin-A: a novel link between obesity and related complications. Int J Obes (Lond). 2015;39:734-41.
Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life sciences. 1997;61:1583-92.
Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the US. Diabetes. 2013;62:49-55.
Laughlin GA, Barrett-Connor E, Cummins KM, Daniels LB, Wassel CL, Ix JH. Sex-specific association of fetuin-A with type 2 diabetes in older community-dwelling adults: the Rancho Bernardo study. Diabetes Care. 2013;36:1994-2000..
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 7. Diabetes technology: standards of care in diabetes—2023. J Diabetes Care. 2023;46(Supplement_1):S111-S27.
Al-Bayati AAH, Al-Khateeb SMJ. The association between glycaemic level and lipid profile with Albuminuria in Iraqi type 2 diabetes patients-A cross sectional study. The Journal of the Pakistan Medical Association. 2021;71:S57-S62.
Shaheed HS, Ali SHJA-RJoMS. Association of carnosinase-1 gene polymorphism with serum carnosine and carnosinease-1 isoform levels in type 2 diabetics with cardiovascular diseases in Iraq. Al-Rafidain Journal of Medical Sciences. 2023;4:109-17.
Shaban A, Abbas SA-R, Abed BAJA-RJoMS. Estimation of Tenascin-C Levels in Iraqi patients with diabetic nephropathy. Al-Rafidain Journal of Medical Sciences. 2023;5(1S):S8-13.
Tan KC, Chow W-S, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care. 2004;27:223-8.
Albayati AA, Rasool Hussein AA. Role of fetuin-a and HSCRP in CVD risk in hypothyroidism iraqi women. J Biochemical Cellular Archives. 2020;20(supplement_2): 3877-81.
Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care. 1992;15:1245-50.
Al-bayati A, Lukka D, Brown AE, Walker M. Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes. J Diabetes Complications. 2016;30:1209-16.
Jirak P, Stechemesser L, Moré E, Franzen M, Topf A, Mirna M, et al. Clinical implications of fetuin-A. Adv Clin Chem. 2019;89:79-130.
Ix JH, Biggs ML, Mukamal KJ, Kizer JR, Zieman SJ, Siscovick DS, et al. Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation. 2012;125:2316-22.
Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350:437-43.
Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002;51:2450-8.
Vionnet N, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, et al. Genomewide search for type 2 diabetes–susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2–diabetes locus on chromosome 1q21–q24. Am J Hum Genet. 2000;67:1470-80.
Song A, Xu M, Bi Y, Xu Y, Huang Y, Li M, Wang T, Wu Y, Liu Y, Li X, Chen Y, Wang W, Ning G. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011;6(4):e19228. Pub Med PMID: 21556362
Lorant DP, Grujicic M, Hoebaus C, Brix J-M, Hoellerl F, Schernthaner G, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011;34:156-61.
Yin L, Cai W-J, Zhu L-Y, Li J, Su X-H, Wang X-L, et al. Association of plasma Fetuin-A and clinical characteristics in patients with new-onset type 2 diabetes mellitus. International journal of clinical and experimental medicine. 2015;8:991. PubMed PMID: 25785085
Iyidir OT, Degertekin CK, Yilmaz BA, Altinova AE, Toruner FB, Bozkurt N, et al. Serum levels of fetuin A are increased in women with gestational diabetes mellitus. Arch Gynecol Obstet. 2015;291:933-7.
Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring H-U, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PloS one. 2008;3(3):e1765. PubMed PMID: 18335040
Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock (Augusta, Ga). 2001;15:181-5.
